Aumolertinib

Chemical formula: C₃₀H₃₅N₇O₂  Molecular mass: 525.285 g/mol  PubChem compound: 121280087

Therapeutic indications

Aumolertinib is indicated for:

Advanced non-small cell lung cancer (NSCLC) with EGFR mutations

Population group: only adults (18 years old or older)

Aumolertinib as monotherapy is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Advanced non-small cell lung cancer (NSCLC) with EGFR T790M positive mutation

Population group: only adults (18 years old or older)

Aumolertinib as monotherapy is indicated for the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Aumolertinib is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Congenital long QT syndrome

Congenital long QT syndrome

Familial history of sudden cardiac death or polymorphic ventricular arrhythmia

at least one of
Sudden cardiac death
Ventricular tachycardia, polymorphic

QT/QTc interval >500 msec, regardless of the correction method

Prolonged QT interval

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2026: AUMSEQA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈